Federica Malighetti

7PUBLICATIONS
24CO-AUTHORS
Molecular targetsCancer diagnosisHaematological tumoursSolid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 19, 2026
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models.

|Mar 13, 2025
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.

Federica Malighetti, Matteo Villa, Alberto Maria Villa

|Jan 08, 2025
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.

Federica Malighetti, Matteo Villa, Mario Mauri

|Oct 31, 2024
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.

Matteo Villa, Geeta G Sharma, Federica Malighetti

|Mar 06, 2024
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients.

Matteo Villa, Federica Malighetti, Elisa Sala

|Nov 25, 2023
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.

Nicoletta Cordani, Luca Mologni, Rocco Piazza

Pageof 2

Frequent Collaborators

7 joint publications

Luca Mologni

6 joint publications

Matteo Villa

5 joint publications

Daniele Ramazzotti

4 joint publications

Nicoletta Cordani